OrbiMed’s Loxo Oncology, Inc LOXO Stock Holding History

OrbiMed’s Portfolio LOXO Stock Details LOXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-330,000	Closed	-$56.4M	–	163
2018 Q3	$56.4M	Sell	330,000 -208,000	-39%	-$35M	0.68%	43
2018 Q2	$93.3M	Sell	538,000 -403,000	-43%	-$60.6M	1.11%	30
2018 Q1	$109M	Sell	941,000 -93,159,036	-99%	-$9.91B	1.35%	22
2017 Q4	$79.2M	Buy	94,100,036 +92,372,036	+5,346%	+$7.7B	1%	34
2017 Q3	$159M	Hold	1,728,000	–	–	1.52%	21
2017 Q2	$139M	Hold	1,728,000	–	–	1.45%	22
2017 Q1	$72.7M	Hold	1,728,000	–	–	0.82%	41
2016 Q4	$55.5M	Hold	1,728,000	–	–	0.71%	43
2016 Q3	$45.2M	Sell	1,728,000 -447,857	-21%	-$11.7M	0.52%	53
2016 Q2	$50.4M	Hold	2,175,857	–	–	0.53%	52
2016 Q1	$59.5M	Hold	2,175,857	–	–	0.63%	43
2015 Q4	$61.9M	Hold	2,175,857	–	–	0.56%	48
2015 Q3	$38M	Hold	2,175,857	–	–	0.38%	53
2015 Q2	$39.2M	Hold	2,175,857	–	–	0.33%	61
2015 Q1	$27.1M	Hold	2,175,857	–	–	0.23%	71
2014 Q4	$25.6M	Hold	2,175,857	–	–	0.24%	66
2014 Q3	$28.6M	Buy	+2,175,857	New	+$28.2M	0.3%	60

Other funds holding LOXO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed's LOXO Position: Q4 2018 in Review

OrbiMed sold out of Loxo Oncology, Inc (LOXO) in Q4 2018, closing a stake of 330,000 shares — an estimated $56.4M sold.

OrbiMed first reported a position in LOXO in Q3 2014 and held it in 17 quarters. The position peaked at $159M in Q3 2017. 232 funds tracked by Wall St. Rank hold LOXO as of Q4 2018.

OrbiMed reported no remaining Loxo Oncology, Inc position as of Q4 2018 after selling out during the quarter.
OrbiMed sold 330,000 Loxo Oncology, Inc shares in Q4 2018, an estimated $56.4M.
OrbiMed first reported a position in Loxo Oncology, Inc in Q3 2014 and held it in 17 quarters.
OrbiMed's Loxo Oncology, Inc position peaked at $159M in Q3 2017.
232 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.